Futura Medical (LON:FUM) Posts Earnings Results

Futura Medical (LON:FUM) posted its quarterly earnings results on Wednesday. The company reported GBX (2.78) EPS for the quarter, Digital Look Earnings reports. The company had revenue of GBX 170 million during the quarter. Futura Medical had a negative return on equity of 104.83% and a negative net margin of 79.41%.

Futura Medical Stock Down 31.5%

FUM traded down GBX 0.41 on Wednesday, reaching GBX 0.89. 50,766,512 shares of the company traded hands, compared to its average volume of 6,546,674. The company has a market cap of £5.17 million, a P/E ratio of -0.43 and a beta of 0.19. Futura Medical has a one year low of GBX 0.75 and a one year high of GBX 15. The firm has a fifty day simple moving average of GBX 1.21 and a two-hundred day simple moving average of GBX 1.43.

Futura Medical Company Profile

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Sexual health issues are prevalent in both men and women. ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.